Poster to highlight lead therapeutic candidates, a series of fully personalized T cell therapies

RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced that a poster presentation highlighting its lead therapeutic candidates, a series of fully personalized T cell therapies, at the American Society of Gene & Cell Therapy (ASGCT) 25^th Annual Meeting taking place May 16-19, 2022 in Washington, D.C.

The details of the poster presentation are as follows:

Abstract Title: Massively Parallel TCR Gene Synthesis and Unbiased Functional Screening: From Decoding Immune Interactome to Fully Personalized TCR-T Therapy

Author: Zi Chen

Date: May 17, 2022 at 5:30PM EDT

Final abstract number: 2022-A-1954-ASGCT

About RootPath

RootPath is a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude. Our Molecular Programming-based DNA fragment assembly technology gives researchers and drug developers unprecedented, equitable access to long synthetic genes and their functional readouts. By applying our technology to mine a patient’s immunome, we create truly personalized T cell therapies for solid tumors. Together, with leading partners, we are exploring new applications across multiple industries. We enable biology at scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005021/en/